Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
about
DBR1 siRNA inhibition of HIV-1 replication.Bone Marrow Gene Therapy for HIV/AIDSPleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammationHIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTRThe efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA.Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library.HIVsirDB: a database of HIV inhibiting siRNAsEngineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs.Three-dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds.Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration.The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-β that activates profibrogenic genes in hepatic stellate cells.Lentviral-mediated RNAi to inhibit target gene expression of the porcine integrin αv subunit, the FMDV receptor, and against FMDV infection in PK-15 cells.Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression.Progress and prospects: RNA-based therapies for treatment of HIV infection.RNA interference and antiviral therapy.Genetic therapies against HIV.A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs.Lentiviral delivery of short hairpin RNAsRNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside.RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?Engineering RNA for targeted siRNA delivery and medical application.The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectorsPotential mechanisms for cell-based gene therapy to treat HIV/AIDS.Synergistic effects of interleukin-7 and pre-T cell receptor signaling in human T cell development.Diverse T-cell differentiation potentials of human fetal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentiviral Delta-like-1-modified mouse stromal cells.Multitarget therapy of malignant cancers by the head-to-tail tandem array multiple shRNAs expression system.Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.A comparison of multiple shRNA expression methods for combinatorial RNAiEvaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy.
P2860
Q21245204-BB0949D1-3BAE-4F7F-9FBF-A0EFD6E373CBQ26801765-A6FFF70E-06CB-44EC-923C-B982FFA4F870Q26858894-AD295B61-4C1B-4B80-BFFB-B3F541490C36Q33292464-E21387A3-8F87-4FFE-92E8-A467013798B2Q33348656-392D1A80-5A41-4F9E-A369-E9284FA5429FQ33719287-7EF92D1B-36FF-46C7-A44D-050BF5FEF669Q34055797-76B5B612-3E5B-4E2C-899A-97F751220F95Q34830422-1C5B8549-911D-4F1D-B7AA-3C7A8F127BADQ34899838-631E46E6-A05A-4134-BB52-464583D7146FQ35023698-202D2732-0575-4426-99BF-AC1120F9B8A3Q35097640-582D9A7C-B0E5-4BE3-91BD-A494C3EFAC20Q35241638-26C7F95B-487C-499A-89DF-68FAA01B4D49Q35988727-649A50C7-956F-4BC6-A2C8-5A7E9477D008Q36868504-62337863-1716-4EE9-ADBD-245F0A1A6DBEQ36944914-514B4496-0E7C-4675-AC26-B1BE24E22A25Q37027170-DB968DE1-52CE-4493-98A6-F4561971FED9Q37331638-D4279201-9899-4878-9276-AD1EA67872E3Q37430557-4C569BB2-E732-4A78-BF13-9B3AC5DAA782Q37566034-889FD070-23E6-492A-B858-7149A5FA41ABQ37678411-E0344AC2-77FD-4DA2-947E-BA48E5F838B7Q37709610-22EFBBE3-1FF3-4C79-A469-10F51B3A30AEQ37830029-B0FC6F85-6A30-4966-8697-7B8C0A08B763Q38267240-2D807C50-7664-412D-9F32-E2DA422FCA42Q39303166-80AB5E20-95AF-498F-929D-5B0B09BEA3D5Q39796195-4F37F665-C465-46CB-AA76-409EE8F96175Q39891654-FF13A041-1573-46F4-8FF8-B553114B46C0Q40523184-F6235D7A-D802-4E06-A71A-1648B4EEF0D0Q41159088-141431FA-FC8F-4F06-B5EC-D3BCF85D0BE3Q42736903-1584022C-BB01-47CA-9E7E-5A5E65B08FC7Q45879357-86C591B2-D53C-4FFA-BFD4-416968E61F33Q50878341-4A016795-4BD6-4C55-B236-210B1F1ECB01Q54854526-085DDDA0-81A2-44B4-A598-5D4F9CC1E8A4
P2860
Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Lentiviral siRNAs targeting mu ...... immunodeficiency virus type 1.
@en
type
label
Lentiviral siRNAs targeting mu ...... immunodeficiency virus type 1.
@en
prefLabel
Lentiviral siRNAs targeting mu ...... immunodeficiency virus type 1.
@en
P2093
P2860
P356
P1433
P1476
Lentiviral siRNAs targeting mu ...... immunodeficiency virus type 1.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302509
P577
2005-07-01T00:00:00Z
P5875
P6179
1033275761